Home

Subscription

April 2024 issue

April 1, 2024 issue

March 2024 issue

February 2024 issue

January 2024 issue



BACK ISSUES

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006


2022 Issues

December 2022 Issue
• Feature: Christmas, Blessings, and Giving
• "O Holy Night"
• Appreciation
• Index for Volume 17, 2022


November 2022 Issue
• Feature: Paying $10 Billion Means Never Having to Say You are Sorry! No Accountability!
• Continued Deception and Arrogance of CVS
• Smoking – The Neglected Pandemic
• A Bipartisan Political Message


October 2022 Issue
• Feature: Rescuing Independent Pharmacy: Part 4 - The Inspiration of Independents
• Politics, Platforms, and Polls


September 2022 Issue
• Feature: Rescuing Independent Pharmacy: Part 3

August 2022 Issue
• Feature: Concepts and Strategies for Rescuing and Rebuilding Independent Pharmacy

July 2022 Issue
• Feature: Independence Day and Independents Day – THE FUTURE OF PHARMACY: THE SUICIDE OF OUR ONCE-NOBLE PROFESSION – UNLESS THERE IS A REVOLUTION!

June 2022 Issue
• Feature: The End of a Distinguished Era for the Philadelphia College of Pharmacy – And Best Wishes for Success in the Next Era!
• New Therapeutic Agents Marketed in the United States in 2021


May 2022 Issue
• Feature: Which is Stronger (Weaker) – AMA or APhA? It Doesn't Matter – They Need a Synergistic Working Relationship!
• Walgreens Passes CVS in a Metric on the Race to the Bottom!
• Paxlovid – A Blemished Success Story


April 2022 Issue
• Feature: LIVE and IN-PERSON
• Chain Lowlights
• Does Anyone Monitor the Regulators?


March 2022 Issue
• Feature: COVID-19 Vaccine Follies – Are There Really Any "Experts"?
• "CVS Ousts Executives After Probe"

• New Drug Review: Atogepant (Qulipta)

February 2022 Issue
• Feature: Medication Errors – If the Public Knew…
• Oral Antivirals for COVID-19 – We Must Learn from Experience
• New Drug Review: Nirmatrelvir/ritonavir (Paxlovid)


January 2022 Issue
• Feature: COVID-19 – Two Years Later
• Continued PBM Deception and Fraud
• New Drug Review: Aducanumab-avwa (Aduhelm)